News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Breaking Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program
Medicus Pharma Ltd. is set to present at Biotech Showcase 2026, highlighting the upcoming readout of its Phase 2 SkinJect clinical data. This presentation underscores the company's strategic focus on advancing select programs through proof-of-concept and pursuing strategic partnerships.
Latest News
FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities
The FDA released eight new guidance documents between April and June 2026, including draft guidances on gene therapy genome editing and payor communications, plus final guidances on pregnancy safety studies and CMC flexibilities for cell and gene therapies. These updates signal the agency's evolving regulatory approach and create both opportunities and compliance requirements for pharmaceutical companies.
Friday Five: ASCO Takeaways, ADA Focus, China Deals & More – Clinical Trials
This week's Friday Five covers standout data from ASCO 2025, including Revolution Medicines' pancreatic cancer results, a preview of the upcoming ADA meeting, and a significant Eli Lilly deal in China. The roundup also highlights ADC safety findings and a new BMS-Hengrui collaboration, providing decision-useful insights for pharma stakeholders.
Pharmalittle: Roche accuses U.S. of 'blackmail,' Supreme Court rules on skinny labels
Roche's chairman calls U.S. drug pricing policy 'blackmail,' while the Supreme Court issues a ruling on skinny labels. This article breaks down what changed, who is affected, and what to watch next.
Ebola 2026: US Response and Travel Restrictions Debate
The 2026 Ebola outbreak has reignited debate over US travel restrictions and the right of American healthcare workers to return home. This article examines the policy, public health, and industry implications.
Senior NIH official pushes MAHA strategy to skeptical ADA audience
Senior NIH official Richard Woychik presented the MAHA strategy to a skeptical ADA audience in New Orleans, emphasizing alignment with NIH priorities. The event highlights growing tension between public health research and political agendas.
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
At the ADA conference, newer GLP-1s were highlighted alongside growing pushback against research funding cuts and a related protest. This article analyzes the developments and their impact on pharma strategy.
Abivax colitis drug hits goal, but cancer cases rattle investors
Abivax's obefazimod met primary efficacy endpoints in a late-stage ulcerative colitis trial, but three cancer cases among treated patients sent shares down 27%. The safety signal, deemed unrelated by investigators, creates uncertainty for regulatory filings and partnership discussions.
Supreme Court sides with generic drug maker in icosapent ethyl patent case
The U.S. Supreme Court unanimously sided with generic drug maker Hikma Pharmaceuticals in a patent case brought by Amarin Pharma over icosapent ethyl. The decision clears the way for Hikma's sale of the generic version in the U.S. market.
Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit — Drug Approvals & Catalyst Tracker
Pfizer, Hikma Pharmaceuticals, and NewLimit are at the center of recent FDA actions. This rundown covers approvals, withdrawals, and upcoming catalysts for pharma BD and investors.
MIRA Pharma Consolidates Global Rights to MIRA-55 and SKNY-1
MIRA Pharmaceuticals amends its MIRALOGX license to secure worldwide exclusive development and commercialization rights for MIRA-55 and SKNY-1, without altering core economics. The move strengthens IP control and follows peer-reviewed data on SKNY-1's obesity and nicotine addiction potential.
4 Biotech Stocks Investors Should Watch in 2026: Market Analysis
This article highlights four biotech stocks—Argenx, BeOne Medicines, IQVIA, and BioNTech—with implied upside ranging from 28% to 41% in 2026. It provides catalyst-driven analysis for investors and pharma BD teams.
Alabama Board of Medical Examiners Issues Warning on Non-FDA-Approved Peptides: What Pharma Teams Need to Know
The Alabama Board of Medical Examiners has officially warned physicians and other medical professionals across the state against prescribing, administering, or compounding non-FDA-approved (research-grade) peptides, calling them unsafe and untested for human use. The action signals growing state-level scrutiny of unregulated peptide markets, with potential implications for pharmaceutical business development, clinical trial recruitment, and regulatory strategy.
Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
Vertex Pharmaceuticals announced that the FDA has accepted its Biologics License Application for accelerated approval of povetacicept in IgA nephropathy, with a PDUFA target date of November 30, 2026. The filing is supported by positive week 36 interim analysis data.
Aurobindo Pharma OAI Classification: Implications for Drug Approvals
The FDA has classified a subsidiary unit of Aurobindo Pharma as Official Action Indicated (OAI), signaling significant regulatory non-compliance. This status threatens pending drug approvals and reshapes the competitive landscape for generic and specialty pharmaceuticals.
Lee, Tuberville Introduce Protections for Homeopathic Medicine with FDA Approval Framework
U.S. Senators Mike Lee and Tommy Tuberville introduced legislation on June 5, 2026, to create an FDA framework for homeopathic medicine. The Homeopathic Drug Product Safety, Quality, and Transparency Act provides a regulatory pathway for homeopathic products without requiring them to fit traditional pharmaceutical categories.
Daraxonrasib Doubles Survival in Pancreatic Cancer: What Pharma Teams Need to Know
Daraxonrasib, a first-in-class RAS inhibitor, nearly doubled overall survival in a Phase III trial for advanced pancreatic cancer. The data marks a potential shift in treatment paradigms for one of the deadliest cancers.
FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis
The FDA has approved Shionogi's ensitrelvir (XOCOVA) as the first and only oral antiviral for post-exposure prophylaxis of COVID-19. This approval addresses a critical prevention gap and introduces a convenient five-day oral regimen.
Generic Drugmakers Gain Key Victory in ‘Skinny Label’ Patent Case
The US Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin's patents in a skinny-label case, overturning a lower court decision. This decision makes generic drugmakers less vulnerable to lawsuits over skinny labels, preserving a key pathway for early market entry on unpatented indications.
Texas AG Investigating Energy Drinks: What Pharma Teams Need to Know
Texas Attorney General Ken Paxton has launched an investigation into Celsius Holdings over marketing practices and caffeine levels in its energy drinks. This article breaks down the development, its implications for pharma and beverage companies, and key questions for industry teams.
FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer
The FDA has approved FoundationOne CDx as a companion diagnostic for inavolisib (Itovebi) in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. This approval expands the targeted therapy landscape and underscores the importance of genomic testing in patient selection.